Nasoryl (Xylometazoline Hydrochloride, Ipratropium Bromide)

Xylometazoline Hydrochloride and Ipratropium Bromide, the active ingredients in Nasoryl, are an alpha‑adrenergic agonist and an anticholinergic presented as a nasal spray for intranasal use. They relieve nasal congestion caused by allergic and non‑allergic rhinitis and the common cold. The combination provides rapid vasoconstriction and reduced secretions, improving airflow through the nasal passages.

GNH USA supplies Nasoryl as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to Good Distribution Practice and offers regulatory support for import and registration in multiple markets.

Nasoryl is indicated for the symptomatic relief of nasal congestion associated with several upper‑respiratory conditions, providing rapid decongestion.

Allergic rhinitis: relieves nasal blockage, reduces mucosal swelling, and improves breathing in patients with allergic rhinitis. Common cold: alleviates nasal congestion, decreases excess mucus, and helps restore normal breathing during the common cold. Non‑allergic rhinitis: decreases glandular secretions and nasal swelling, enhancing airflow for individuals with non‑allergic rhinitis.

Nasoryl may be associated with a range of adverse reactions, which are generally classified by frequency.

Common Side Effects: - Nasal irritation or burning sensation - Dryness of the nasal mucosa - Sneezing - Headache - Nasal crusting - Taste disturbance - Throat irritation

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis, angioedema) - Persistent nasal bleeding (epistaxis) - Vision changes - Elevated intraocular pressure

Before using Nasoryl, consider the following precautions to ensure safe use.

- Indication: Use only for short‑term relief, typically not exceeding three consecutive days. - Contraindication: Avoid in patients with known hypersensitivity to either active ingredient. - Caution: Use with care in individuals with hypertension or cardiovascular disease. - Pregnancy: Safety has not been established; consult a healthcare professional before use. - Interaction: Do not combine with other nasal decongestants to prevent excessive vasoconstriction. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Nasoryl can interact with other medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): may increase risk of hypertensive crisis when combined with alpha‑adrenergic agonists. - Other intranasal vasoconstrictors (e.g., oxymetazoline): can cause excessive nasal vasoconstriction and rebound congestion.

Moderate Interactions (Monitor Closely): - Anticholinergic drugs (e.g., atropine): additive anticholinergic effects may increase dryness. - Beta‑blockers: may blunt systemic cardiovascular response to alpha‑agonist. - Antihistamines: combined use may enhance drying of nasal mucosa.